Novartis Receives Third FDA Approval For Oral Fabhalta

 

• Phase III study showed sustained proteinuria reduction at one year with favorable safety1
• Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3
• C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4
• Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence
• https://www.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g